Key result
Phase II cardiac rehabilitation yields ~56 percentage point gain in low-risk 6MWT status in PAH.
Why the study?
Pulmonary arterial hypertension significantly reduces functional capacity and quality of life, and conventional therapy often yields limited clinical improvement. This study evaluated the effect of phase II cardiac rehabilitation on functional capacity, quality of life, and mean pulmonary artery pressure in these patients.
Does phase II cardiac rehabilitation improve functional capacity, quality of life, and mean pulmonary artery pressure in patients with pulmonary arterial hypertension?
Does phase II cardiac rehabilitation improve functional capacity, quality of life, and mean pulmonary artery pressure in patients with pulmonary arterial hypertension?
Phase II cardiac rehabilitation significantly improves 6MWT functional capacity and EQ-5D-3L quality of life while reducing mean pulmonary artery pressure in patients with pulmonary arterial hypertension.
Cardiac rehab may aid functional gains in PAH; leaves open randomized confirmation before practice change.
Background Pulmonary arterial hypertension (PAH) is a progressive condition that significantly reduces functional capacity and quality of life. Conventional therapy often results in limited clinical improvement. Objectives This study aimed to evaluate the effect of phase II cardiac rehabilitation on functional capacity, quality of life, and mean pulmonary artery pressure (mPAP) in patients with PAH. Methods This quasi-experimental study was conducted from December 2024 to February 2025. Patients were divided into an intervention group (cardiac rehabilitation) and a control group (pharmacological therapy alone). Outcome measures included the six-minute walk test (6MWT), EuroQol-5D-3L (EQ-5D-3L), visual analogue scale (EQ-VAS), and mPAP. Statistical analyses were performed with p < 0.05 considered statistically significant. Results A total of 36 patients were enrolled. The intervention group demonstrated significant improvements in 6MWT performance (low-risk category increased from 27.8% to 83.3%, p < 0.001), a reduction in mPAP (moderate-to-severe category decreased from 83.3% to 66.7%, p = 0.006), and improved EQ-5D-3L quality-of-life scores (serious impairment decreased from 27.8% to 0%, p = 0.009). The greatest benefits were observed in patients with World Health Organization functional class (WHO-FC) III and in those who completed ≥10 rehabilitation sessions. Conclusion Phase II cardiac rehabilitation significantly improves functional capacity and quality of life while reducing mPAP in patients with PAH and may be considered an effective adjunctive therapy in clinical management.
No takes yet. Share an insight, caveat, or question.
A A L Lubis (2026) studied Pulmonary arterial hypertension (n=36). Phase II cardiac rehabilitation vs. Pharmacological therapy alone was evaluated on Six-minute walk test (6MWT) low-risk category performance (p=<0.001). Phase II cardiac rehabilitation significantly improved 6MWT performance (low-risk category increased from 27.8% to 83.3%, p<0.001) and reduced mPAP (p=0.006) in PAH patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: